Sage Therapeutics Inc. (SAGE) has faced a challenging year to date, with its share price plummeting 77% from its 52-week high of $22.86 in January, to trade around $6.
This biopharmaceutical company has two FDA-approved treatments indicated for postpartum depression and a robust pipeline to target unmet needs in brain health.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com